19.7% Average Loss With Tirzepatide at 176 Weeks
This prespecified three-year SURMOUNT-1 analysis followed participants with obesity and prediabetes. It reported dose-specific average weight change and fewer diagnosed type 2 diabetes cases during the 176-week treatment period. Those findings are trial results under specific eligibility and follow-up conditions—not a personal prediction or an FDA-approved diabetes-prevention claim.
At week 176, mean body-weight change was −12.3% with tirzepatide 5 mg, −18.7% with 10 mg, and −19.7% with 15 mg, versus −1.3% with placebo.
Across the tirzepatide groups, 1.3% of participants and 13.3% of placebo participants developed type 2 diabetes by week 176. After 17 weeks off treatment, those figures were 2.4% and 13.7%, respectively. Gastrointestinal events were the most common non-COVID-19 adverse events; they were mostly mild to moderate and occurred mainly during the first 20 weeks of dose escalation.
Turn the study result into a better program comparison
If this longer-term result prompts you to explore GLP-1 care, compare the practical details the study did not test: available plans, clinician access, medication status, follow-up, public price terms, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 1,032 adults with obesity and prediabetes from the 2,539-person SURMOUNT-1 parent trial
- Follow-up
- 176-week treatment period; 193 weeks including the off-treatment follow-up
- Treatment comparison
- Once-weekly subcutaneous tirzepatide 5 mg, 10 mg, or 15 mg compared with placebo for 176 weeks
- Study design
- Phase 3, multicenter, double-blind, randomized, placebo-controlled extension analysis
A study result is not a personal treatment plan
The study does not establish a diabetes-prevention indication, decide whether tirzepatide is appropriate for an individual, or determine what a provider can prescribe or insurance will cover. It also does not compare online providers, pharmacies, or program quality. Those clinical and coverage questions require a licensed clinician and current prescribing information.
Compare tirzepatide and semaglutide programsWhat this result does not show
- The three-year analysis included the 1,032 parent-trial participants with prediabetes, not people without prediabetes or people with established diabetes.
- The additional treatment period included participants who completed the initial 72-week phase, which may limit applicability to people who cannot continue treatment or long-term follow-up.
- The off-treatment observation lasted 17 weeks. The higher diabetes incidence after cessation means the study does not establish durability after longer-term discontinuation.
- The trial measured diabetes diagnosis and body weight, not diabetes complications, cardiovascular events, mortality, provider quality, affordability, or individual outcomes.
- The study was funded by Eli Lilly; the peer-reviewed paper and disclosure materials are linked at the end of this article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at New England Journal of Medicine